Now I have all the information needed to produce the consolidated review.

---

## Summary

GANDALF proposes a generative framework for data augmentation in cancer drug response prediction (DRP). It uses denoising diffusion probabilistic models (DDPMs), variational autoencoders, transformers, and multi-task learning to synthesize patient-like mutation profiles from cell line data, explicitly modeling the distribution shift between the two domains. The generated samples and their pseudo-labels are then used alongside real patient data to train a downstream DRP classifier.

## Strengths

- **Novel direct-augmentation approach with domain-specific modeling.** GANDALF is the first DRP method to generate synthetic patient-like mutation profiles *and* their response labels directly from cell line data, explicitly modeling the distribution shift $P(X_c) \neq P(X_p)$ and $domain(y_c) \neq domain(y_p)$ (Section 3.2.1–3.2.2). This directly targets the key limitation of prior transfer-learning methods that only augment in a shared representation space.

- **Empirical gains over existing methods on the evaluated drugs.** Tables 1 and 2 show GANDALF achieving best AUROC on 4 of 5 drugs (Flu, Gem, Pac, Tem) and best AUPRC on 3 of 5 drugs (Flu, Gem, Pac), with improvements up to 10.96% over prior SOTA. It also outperforms both a naive Gaussian perturbation baseline and a majority-vote pseudolabeling strategy.

- **Ablation study confirms component contributions.** Removing the MTL head, cross-attention loss, or transformer encoder degrades both AUROC and AUPRC relative to the full model (Table 2, Ablation), providing evidence that each design choice is functional.

- **Principled handling of the label-invariance problem.** The paper correctly identifies that genomic data augmentation for DRP is difficult because label-invariant transformations are not known. GANDALF's use of labelled cell line data to generate both samples and labels is a sound workaround.

## Weaknesses

### Major

1. **Evaluation restricted to only 5 of 56 drugs, with no aggregate metrics.** The paper reports results for exactly 5 drugs (Cisplatin, Paclitaxel, 5-Fluorouracil, Gemcitabine, Temozolomide) out of 56 present in the patient dataset, justified only as "drugs with samples available in all 3 test folds." There is no pooled or aggregate metric across all drugs, and no discussion of how many drugs are excluded by this criterion or whether the 5 are representative. The claim that GANDALF "outperforms state-of-the-art DRP models" is based on this narrow subset, so its generality is unknown. This is the single most impactful gap in the evaluation.

2. **No uncertainty or variance reported for any experimental result.** Tables 1 and 2 report point estimates (AUROC, AUPRC) without standard deviations, confidence intervals, or significance tests. With only 669 total patient samples split across 3 folds and 5 drugs, per-drug per-fold test sizes are necessarily small. The reported margins between GANDALF and the second-best method are often narrow (e.g., 0.7626 vs. 0.7560 AUROC against majority-vote pseudolabeling), and without variance estimates there is no way to assess whether these differences are meaningful or due to chance. This omission undermines the paper's central empirical claims.

3. **Quality of generated synthetic samples is not validated.** The paper states "We examined the quality of the generated samples by comparing the distributions against the original patient data" (Section 5), but no results, figures, or quantitative metrics from this analysis are presented. The diffusion models are trained on limited patient data (669 samples total, split across folds, with only 142 GENIE samples for transformer pretraining), and there is no evidence that the generated $X_{aug}$ samples actually resemble realistic patient mutation profiles. Since the entire pipeline depends on the fidelity of these samples, this is a structural gap — without validation, the core mechanism of the method is unsubstantiated.

### Minor

4. **Weak augmentation baselines inflate perceived advantage.** The paper compares GANDALF only against a naive Gaussian perturbation (AUROC 0.6158 vs. 0.7626) and no augmentation. While the paper correctly notes that no established label-invariant augmentation methods exist for this task, the comparison would be strengthened by constructing a more competitive baseline (e.g., training a VAE on patient data alone for generation, or mixing cell-line and patient features with reweighted labels). The current baselines set a low bar.

5. **Overstated novelty claim regarding "first to tackle" data augmentation.** The paper states "We are the first to tackle, through a novel data augmentation approach, the challenging problem of limited labels... in cancer drug response prediction" (bullet 1, Section 1), despite acknowledging earlier in the same section that "WISER (Shubham et al., 2024) performs data augmentation by pseudolabelling unlabelled patient profiles." The novelty is in the *mechanism* (generative diffusion + domain-aware MTL), not in being the first to augment. This is a minor rhetorical overclaim but should be corrected.

6. **Threshold selection for confident sample binning is underspecified.** The upper and lower thresholds $t_u$ and $t_l$ for binning pseudo-labels are named but their values are not reported, and no sensitivity analysis is provided. Since the downstream classifier depends on which samples are retained, this is a practically relevant hyperparameter that would meaningfully affect results.

### Trivial

- None beyond what is addressed above.

## Nice-to-Haves

- Reporting per-drug per-fold sample sizes would help readers assess whether test sets are large enough to yield stable metrics.
- While not standard practice for every DRP benchmark, bootstrapped confidence intervals across folds or repeated training runs would substantially strengthen the statistical case.
- A brief analysis of generated samples (e.g., UMAP visualization comparing real patients, real cell lines, and generated samples) would directly address concern #3.

## Removed Points

- **CORAL alignment assumption criticism** (harsh critic's "Other Observations", bullet 2): The paper justifies CORAL as a standard domain alignment technique used to match covariance structure between latent representations. This is a well-established approach (Sun et al., 2016), and the reviewer provides no concrete evidence that the assumption is violated. The criticism is speculative and does not constitute a valid weakness.
- **Transformer T_e PFS training detail** (harsh critic's "Other Observations", bullet 3): The paper properly references (Jayagopal et al., 2024) for the training details. Requiring those details to be repeated is not a substantive weakness of this paper.
- **Cancer type overlap concern** (harsh critic's "Other Observations", bullet 4): The paper explicitly mentions tumor-type-specific analysis as future work. This is a reasonable scope decision, not a flaw in the current work.
- **Treatment of 142 GENIE samples as DDPM training data** (part of harsh critic's point 3): The critic conflates the 142 GENIE samples used for T_e pretraining with DDPM training data. The DDPMs are trained on VAE latent representations from the full CCLE (1197) and patient (669) datasets. The patient-side DDPM training data is 669, not 142.

## Novel Insights

None beyond the paper's own contributions. The reviews do not surface any observation about the method or results that the paper itself does not already state or imply.

## Suggestions

1. **Broaden the evaluation.** Report pooled AUROC/AUPRC (with bootstrapped confidence intervals) across all drugs that appear in the test set, even if per-drug metrics are noisy. This is the single most impactful improvement. If samples are too few for meaningful per-drug evaluation, state the sample sizes per drug and discuss the limitation honestly.
2. **Add variance estimates** to all tables — standard deviations across folds or across repeated runs with different random seeds.
3. **Provide a quantitative or qualitative analysis** of generated sample quality (e.g., UMAP/t-SNE comparison of real patients, real cell lines, and generated $X_{aug}$, or a check of whether co-occurring mutation patterns in real data are preserved in generated data).

## Score and Decision

The paper addresses a genuine problem with a technically well-motivated pipeline. The architecture is carefully designed and each component is justified. However, the experimental evaluation has three serious gaps: (1) results are shown for only 5 of 56 drugs, (2) no variance or confidence measures are reported, and (3) the quality of generated synthetic samples — the foundation of the whole approach — is asserted but not demonstrated. These gaps collectively prevent the paper from convincingly supporting its core claims. The method is promising, but as submitted, the evidence is insufficient. I recommend rejection with the possibility of resubmission after a substantially strengthened evaluation.

MY FINAL SCORE: <pineapple>4.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>